A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Clinical trial NCT07081997 · RECRUITING

Trial details

NCT number: NCT07081997
Sponsor: Ascendis Pharma Bone Diseases A/S
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hypoparathyroidism Endocrine System Diseases Parathyroid Diseases

Start date: 2026-05-07
Primary completion: 2027-06-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.